Diseases /
Acute Myeloid Leukemia
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification). [1]
Acute myeloid leukemias most frequently harbor alterations in DNMT3A, NPM1, ASXL1, TET2, and ETV6 [2].
NPM1 Mutation, NPM1 W288Cfs*12, DNMT3A Mutation, ASXL1 Mutation, and TET2 Mutation are the most common alterations in acute myeloid leukemia [2].
Biomarker-Directed Therapies
FLT3, IDH1, and IDH2 are the most frequent predictive biomarkers for acute myeloid leukemia therapies.
Of the biomarker-directed therapies for acute myeloid leukemia, 4 are FDA-approved in at least one setting and 5 have NCCN guidelines in at least one setting [3].
Enasidenib +
Disease is predicted to be sensitive: -
Gilteritinib +
Disease is predicted to be sensitive: -
Ivosidenib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): First Line of Therapy (FDA), Refractory (FDA, NCCN), Relapse (FDA, NCCN) |
| Note: Approved for adult patients with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation. |
Midostaurin +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Consolidation Therapy (FDA, NCCN, MCG), Treatment Induction (FDA, NCCN, MCG) |
| Note: FDA-approved, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation, for adults with newly diagnosed, FLT3-mutated AML. |
Sorafenib +
Disease is predicted to be sensitive: -
Clinical Trials
There are 420 clinical trials for acute myeloid leukemia, of which 310 are open and 110 are completed or closed. Of the trials that contain acute myeloid leukemia as an inclusion criterion, 4 are early phase 1 (4 open), 128 are phase 1 (82 open), 87 are phase 1/phase 2 (70 open), 134 are phase 2 (101 open), 10 are phase 2/phase 3 (8 open), 38 are phase 3 (32 open), 2 are phase 4 (2 open), and 17 are no phase specified (11 open).
FLT3, KMT2A, and MECOM are the most frequent gene inclusion criteria for acute myeloid leukemia clinical trials [3].
Cytarabine, fludarabine, and azacitidine are the most common interventions in acute myeloid leukemia clinical trials.
Significant Genes in Acute Myeloid Leukemia
ABL1 +
ABL1 is mutated in 0.43% of acute myeloid leukemia patients [2].
ABL1 is an inclusion eligibility criterion in 95 clinical trials for acute myeloid leukemia, of which 71 are open and 24 are closed. Of the trials that contain ABL1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 25 are phase 1 (14 open), 18 are phase 1/phase 2 (15 open), 40 are phase 2 (32 open), 3 are phase 2/phase 3 (3 open), 6 are phase 3 (4 open), and 2 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in acute myeloid leukemia trials with ABL1 mutations as inclusion criteria [3].
ABL2 +
ABL2 is mutated in 14.29% of acute myeloid leukemia patients [2].
ABL2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ABL2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Ect-001 expanded cord blood is the most frequent therapy in acute myeloid leukemia trials with ABL2 mutations as inclusion criteria [3].
AFF1 +
AFF1 is an inclusion eligibility criterion in 97 clinical trials for acute myeloid leukemia, of which 66 are open and 31 are closed. Of the trials that contain AFF1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 28 are phase 1 (15 open), 16 are phase 1/phase 2 (13 open), 38 are phase 2 (29 open), 2 are phase 2/phase 3 (2 open), 8 are phase 3 (4 open), and 4 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in acute myeloid leukemia trials with AFF1 mutations as inclusion criteria [3].
ASXL1 +
ASXL1 is mutated in 18.71% of acute myeloid leukemia patients [2].
ASXL1 is an inclusion eligibility criterion in 7 clinical trials for acute myeloid leukemia, of which 6 are open and 1 is closed. Of the trials that contain ASXL1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [3].
Allogeneic hematopoietic stem cell transplantation, azacitidine, and antineoplastic immune cell are the most frequent therapies in acute myeloid leukemia trials with ASXL1 mutations as inclusion criteria [3].
ATM +
ATM is mutated in 2.72% of acute myeloid leukemia patients [2].
ATM is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ATM status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Mln9708, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in acute myeloid leukemia trials with ATM mutations as inclusion criteria [3].
BCL2 +
BCL2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCL2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
Bet inhibitor gsk525762 is the most frequent therapy in acute myeloid leukemia trials with BCL2 mutations as inclusion criteria [3].
BCL6 +
BCL6 is mutated in 0.37% of acute myeloid leukemia patients [2].
BCL6 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
Bet inhibitor gsk525762 is the most frequent therapy in acute myeloid leukemia trials with BCL6 mutations as inclusion criteria [3].
BCOR +
BCOR is mutated in 9.4% of acute myeloid leukemia patients [2].
BCOR is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCOR status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
Busulfan, fludarabine, and venetoclax are the most frequent therapies in acute myeloid leukemia trials with BCOR mutations as inclusion criteria [3].
BCR +
BCR is an inclusion eligibility criterion in 95 clinical trials for acute myeloid leukemia, of which 71 are open and 24 are closed. Of the trials that contain BCR status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 25 are phase 1 (14 open), 18 are phase 1/phase 2 (15 open), 40 are phase 2 (32 open), 3 are phase 2/phase 3 (3 open), 6 are phase 3 (4 open), and 2 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in acute myeloid leukemia trials with BCR mutations as inclusion criteria [3].
BIRC3 +
BIRC3 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Mln9708, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in acute myeloid leukemia trials with BIRC3 mutations as inclusion criteria [3].
CBFA2T3 +
CBFA2T3 is mutated in 1.32% of acute myeloid leukemia patients [2].
CBFA2T3 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain CBFA2T3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [3].
Alloantigen-specific allogeneic type 1 regulatory t cells t-allo10, non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, and rabbit anti-thymocyte globulin are the most frequent therapies in acute myeloid leukemia trials with CBFA2T3 mutations as inclusion criteria [3].
CBFB +
CBFB is mutated in 2.38% of acute myeloid leukemia patients [2].
CBFB is an inclusion eligibility criterion in 59 clinical trials for acute myeloid leukemia, of which 29 are open and 30 are closed. Of the trials that contain CBFB status and acute myeloid leukemia as inclusion criteria, 19 are phase 1 (7 open), 8 are phase 1/phase 2 (5 open), 16 are phase 2 (8 open), 3 are phase 2/phase 3 (3 open), 6 are phase 3 (3 open), 1 is phase 4 (1 open), and 6 are no phase specified (2 open) [3].
Cytarabine, fludarabine, and total-body irradiation are the most frequent therapies in acute myeloid leukemia trials with CBFB mutations as inclusion criteria [3].
CBL +
CBL is mutated in 2.75% of acute myeloid leukemia patients [2].
CBL is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 1 is open and 1 is closed. Of the trials that contain CBL status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].
Anti-epha3 monoclonal antibody kb004, busulfan, and fludarabine are the most frequent therapies in acute myeloid leukemia trials with CBL mutations as inclusion criteria [3].
CEBPA +
CEBPA is mutated in 4.19% of acute myeloid leukemia patients [2].
CEBPA is an inclusion eligibility criterion in 9 clinical trials for acute myeloid leukemia, of which 9 are open and 0 are closed. Of the trials that contain CEBPA status and acute myeloid leukemia as inclusion criteria, 5 are phase 2 (5 open), 3 are phase 2/phase 3 (3 open), and 1 is no phase specified (1 open) [3].
Idarubicin, cytarabine, and etoposide are the most frequent therapies in acute myeloid leukemia trials with CEBPA mutations as inclusion criteria [3].
CREBBP +
CREBBP is mutated in 3.3% of acute myeloid leukemia patients [2].
CREBBP is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain CREBBP status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
Alloantigen-specific allogeneic type 1 regulatory t cells t-allo10, non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, and rabbit anti-thymocyte globulin are the most frequent therapies in acute myeloid leukemia trials with CREBBP mutations as inclusion criteria [3].
CRLF2 +
CRLF2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains CRLF2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Ect-001 expanded cord blood is the most frequent therapy in acute myeloid leukemia trials with CRLF2 mutations as inclusion criteria [3].
CSF1R +
CSF1R is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Ect-001 expanded cord blood is the most frequent therapy in acute myeloid leukemia trials with CSF1R mutations as inclusion criteria [3].
DEK +
DEK is an inclusion eligibility criterion in 86 clinical trials for acute myeloid leukemia, of which 66 are open and 20 are closed. Of the trials that contain DEK status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 23 are phase 1 (15 open), 15 are phase 1/phase 2 (12 open), 37 are phase 2 (30 open), 2 are phase 2/phase 3 (2 open), 6 are phase 3 (4 open), and 2 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in acute myeloid leukemia trials with DEK mutations as inclusion criteria [3].
DNMT3A +
DNMT3A is mutated in 21.37% of acute myeloid leukemia patients [2].
DNMT3A is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 1 is open and 1 is closed. Of the trials that contain DNMT3A status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
Allogeneic cd56-positive cd3-negative natural killer cells, interleukin-2, and superagonist interleukin-15:interleukin-15 receptor alphasu/fc fusion complex alt-803 are the most frequent therapies in acute myeloid leukemia trials with DNMT3A mutations as inclusion criteria [3].
ELL +
ELL is an inclusion eligibility criterion in 89 clinical trials for acute myeloid leukemia, of which 59 are open and 30 are closed. Of the trials that contain ELL status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 26 are phase 1 (13 open), 16 are phase 1/phase 2 (13 open), 34 are phase 2 (26 open), 1 is phase 2/phase 3 (1 open), 7 are phase 3 (3 open), and 4 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in acute myeloid leukemia trials with ELL mutations as inclusion criteria [3].
EPOR +
EPOR is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains EPOR status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Ect-001 expanded cord blood is the most frequent therapy in acute myeloid leukemia trials with EPOR mutations as inclusion criteria [3].
ERBB2 +
ERBB2 is mutated in 1.09% of acute myeloid leukemia patients [2].
ERBB2 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and acute myeloid leukemia as inclusion criteria, 3 are phase 1/phase 2 (3 open) [3].
Autologous nkg2d car-expressing t-lymphocytes cm-cs1, gm-csf, and galinpepimut-s are the most frequent therapies in acute myeloid leukemia trials with ERBB2 mutations as inclusion criteria [3].
ERG +
ERG is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ERG status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
Alloantigen-specific allogeneic type 1 regulatory t cells t-allo10 is the most frequent therapy in acute myeloid leukemia trials with ERG mutations as inclusion criteria [3].
ETV6 +
ETV6 is mutated in 17.38% of acute myeloid leukemia patients [2].
ETV6 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in acute myeloid leukemia trials with ETV6 mutations as inclusion criteria [3].
EZH2 +
EZH2 is mutated in 4.69% of acute myeloid leukemia patients [2].
EZH2 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain EZH2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
Azacitidine, busulfan, and fludarabine are the most frequent therapies in acute myeloid leukemia trials with EZH2 mutations as inclusion criteria [3].
FGF2 +
FGF2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGF2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
Azacitidine and nintedanib are the most frequent therapies in acute myeloid leukemia trials with FGF2 mutations as inclusion criteria [3].
FGFR3 +
FGFR3 is mutated in 1.27% of acute myeloid leukemia patients [2].
FGFR3 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 1 is open and 1 is closed. Of the trials that contain FGFR3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
Cdk/jak2/flt3 inhibitor tg02 citrate, mln9708, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in acute myeloid leukemia trials with FGFR3 mutations as inclusion criteria [3].
FLT3 +
FLT3 is mutated in 11.3% of acute myeloid leukemia patients [2].
FLT3 is an inclusion eligibility criterion in 153 clinical trials for acute myeloid leukemia, of which 113 are open and 40 are closed. Of the trials that contain FLT3 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 37 are phase 1 (23 open), 31 are phase 1/phase 2 (22 open), 59 are phase 2 (44 open), 3 are phase 2/phase 3 (3 open), 17 are phase 3 (15 open), and 5 are no phase specified (5 open) [3].
Gilteritinib, midostaurin, and sorafenib are currently approved for use in patients with FLT3 mutation in acute myeloid leukemia [3].
Fludarabine, cyclophosphamide, and cytarabine are the most frequent therapies in acute myeloid leukemia trials with FLT3 mutations as inclusion criteria [3].
FUS +
FUS is mutated in 0.37% of acute myeloid leukemia patients [2].
FUS is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FUS status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
Alloantigen-specific allogeneic type 1 regulatory t cells t-allo10 is the most frequent therapy in acute myeloid leukemia trials with FUS mutations as inclusion criteria [3].
GLIS2 +
GLIS2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains GLIS2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in acute myeloid leukemia trials with GLIS2 mutations as inclusion criteria [3].
HOXA9 +
HOXA9 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains HOXA9 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in acute myeloid leukemia trials with HOXA9 mutations as inclusion criteria [3].
HRAS +
HRAS is mutated in 2.27% of acute myeloid leukemia patients [2].
HRAS is an inclusion eligibility criterion in 5 clinical trials for acute myeloid leukemia, of which 3 are open and 2 are closed. Of the trials that contain HRAS status and acute myeloid leukemia as inclusion criteria, 3 are phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
Allogeneic hematopoietic stem cell transplantation, allogeneic cd56-positive cd3-negative natural killer cells, and antineoplastic immune cell are the most frequent therapies in acute myeloid leukemia trials with HRAS mutations as inclusion criteria [3].
IDH1 +
IDH1 is mutated in 8.17% of acute myeloid leukemia patients [2].
IDH1 is an inclusion eligibility criterion in 10 clinical trials for acute myeloid leukemia, of which 9 are open and 1 is closed. Of the trials that contain IDH1 status and acute myeloid leukemia as inclusion criteria, 3 are phase 1 (2 open), 5 are phase 1/phase 2 (5 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [3].
Ivosidenib is currently approved for use in patients with IDH1 mutation in acute myeloid leukemia [3].
Ivosidenib, azacitidine, and idh2 inhibitor ag-221 are the most frequent therapies in acute myeloid leukemia trials with IDH1 mutations as inclusion criteria [3].
IDH2 +
IDH2 is mutated in 10.59% of acute myeloid leukemia patients [2].
IDH2 is an inclusion eligibility criterion in 12 clinical trials for acute myeloid leukemia, of which 12 are open and 0 are closed. Of the trials that contain IDH2 status and acute myeloid leukemia as inclusion criteria, 3 are phase 1 (3 open), 4 are phase 1/phase 2 (4 open), 4 are phase 2 (4 open), and 1 is phase 3 (1 open) [3].
Enasidenib is currently approved for use in patients with IDH2 mutation in acute myeloid leukemia [3].
Idh2 inhibitor ag-221, azacitidine, and enasidenib are the most frequent therapies in acute myeloid leukemia trials with IDH2 mutations as inclusion criteria [3].
IGH +
IGH is an inclusion eligibility criterion in 4 clinical trials for acute myeloid leukemia, of which 3 are open and 1 is closed. Of the trials that contain IGH status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].
Cyclophosphamide, fludarabine, and cdk/jak2/flt3 inhibitor tg02 citrate are the most frequent therapies in acute myeloid leukemia trials with IGH mutations as inclusion criteria [3].
IKZF1 +
IKZF1 is mutated in 1.92% of acute myeloid leukemia patients [2].
IKZF1 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain IKZF1 status and acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].
Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most frequent therapies in acute myeloid leukemia trials with IKZF1 mutations as inclusion criteria [3].
IL7R +
IL7R is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains IL7R status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Ect-001 expanded cord blood is the most frequent therapy in acute myeloid leukemia trials with IL7R mutations as inclusion criteria [3].
JAK1 +
JAK1 is mutated in 1.19% of acute myeloid leukemia patients [2].
JAK1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains JAK1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Ect-001 expanded cord blood is the most frequent therapy in acute myeloid leukemia trials with JAK1 mutations as inclusion criteria [3].
JAK2 +
JAK2 is mutated in 3.13% of acute myeloid leukemia patients [2].
JAK2 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain JAK2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].
Antineoplastic immune cell, ect-001 expanded cord blood, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in acute myeloid leukemia trials with JAK2 mutations as inclusion criteria [3].
JAK3 +
JAK3 is mutated in 0.45% of acute myeloid leukemia patients [2].
JAK3 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains JAK3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Ect-001 expanded cord blood is the most frequent therapy in acute myeloid leukemia trials with JAK3 mutations as inclusion criteria [3].
KAT6A +
KAT6A is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain KAT6A status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
Alloantigen-specific allogeneic type 1 regulatory t cells t-allo10, non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, and rabbit anti-thymocyte globulin are the most frequent therapies in acute myeloid leukemia trials with KAT6A mutations as inclusion criteria [3].
KDM5A +
KDM5A is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KDM5A status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in acute myeloid leukemia trials with KDM5A mutations as inclusion criteria [3].
KIT +
KIT is mutated in 2.2% of acute myeloid leukemia patients [2].
KIT is an inclusion eligibility criterion in 28 clinical trials for acute myeloid leukemia, of which 20 are open and 8 are closed. Of the trials that contain KIT status and acute myeloid leukemia as inclusion criteria, 7 are phase 1 (5 open), 5 are phase 1/phase 2 (3 open), 10 are phase 2 (7 open), 2 are phase 2/phase 3 (2 open), 3 are phase 3 (2 open), and 1 is no phase specified (1 open) [3].
Fludarabine, cytarabine, and cyclophosphamide are the most frequent therapies in acute myeloid leukemia trials with KIT mutations as inclusion criteria [3].
KMT2A +
KMT2A is mutated in 1.44% of acute myeloid leukemia patients [2].
KMT2A is an inclusion eligibility criterion in 133 clinical trials for acute myeloid leukemia, of which 87 are open and 46 are closed. Of the trials that contain KMT2A status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 37 are phase 1 (19 open), 23 are phase 1/phase 2 (19 open), 51 are phase 2 (36 open), 5 are phase 2/phase 3 (5 open), 10 are phase 3 (5 open), and 6 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in acute myeloid leukemia trials with KMT2A mutations as inclusion criteria [3].
KRAS +
KRAS is mutated in 3.77% of acute myeloid leukemia patients [2].
KRAS is an inclusion eligibility criterion in 10 clinical trials for acute myeloid leukemia, of which 6 are open and 4 are closed. Of the trials that contain KRAS status and acute myeloid leukemia as inclusion criteria, 3 are phase 1 (2 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (2 open) [3].
Binimetinib, busulfan, and fludarabine are the most frequent therapies in acute myeloid leukemia trials with KRAS mutations as inclusion criteria [3].
MDM2 +
MDM2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
Mdm2/mdmx inhibitor alrn-6924 and cytarabine are the most frequent therapies in acute myeloid leukemia trials with MDM2 mutations as inclusion criteria [3].
MDM4 +
MDM4 is mutated in 0.73% of acute myeloid leukemia patients [2].
MDM4 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
Mdm2/mdmx inhibitor alrn-6924 and cytarabine are the most frequent therapies in acute myeloid leukemia trials with MDM4 mutations as inclusion criteria [3].
MECOM +
MECOM is mutated in 1.51% of acute myeloid leukemia patients [2].
MECOM is an inclusion eligibility criterion in 117 clinical trials for acute myeloid leukemia, of which 93 are open and 24 are closed. Of the trials that contain MECOM status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 33 are phase 1 (25 open), 24 are phase 1/phase 2 (19 open), 47 are phase 2 (38 open), 3 are phase 2/phase 3 (3 open), 7 are phase 3 (5 open), and 2 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in acute myeloid leukemia trials with MECOM mutations as inclusion criteria [3].
MLF1 +
MLF1 is an inclusion eligibility criterion in 45 clinical trials for acute myeloid leukemia, of which 42 are open and 3 are closed. Of the trials that contain MLF1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 15 are phase 1 (14 open), 9 are phase 1/phase 2 (9 open), 16 are phase 2 (14 open), 2 are phase 2/phase 3 (2 open), and 2 are phase 3 (2 open) [3].
Azacitidine, fludarabine, and cyclophosphamide are the most frequent therapies in acute myeloid leukemia trials with MLF1 mutations as inclusion criteria [3].
MLLT1 +
MLLT1 is an inclusion eligibility criterion in 90 clinical trials for acute myeloid leukemia, of which 60 are open and 30 are closed. Of the trials that contain MLLT1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 26 are phase 1 (13 open), 16 are phase 1/phase 2 (13 open), 35 are phase 2 (27 open), 1 is phase 2/phase 3 (1 open), 7 are phase 3 (3 open), and 4 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in acute myeloid leukemia trials with MLLT1 mutations as inclusion criteria [3].
MLLT10 +
MLLT10 is an inclusion eligibility criterion in 89 clinical trials for acute myeloid leukemia, of which 59 are open and 30 are closed. Of the trials that contain MLLT10 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 26 are phase 1 (13 open), 16 are phase 1/phase 2 (13 open), 34 are phase 2 (26 open), 1 is phase 2/phase 3 (1 open), 7 are phase 3 (3 open), and 4 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in acute myeloid leukemia trials with MLLT10 mutations as inclusion criteria [3].
MLLT3 +
MLLT3 is an inclusion eligibility criterion in 102 clinical trials for acute myeloid leukemia, of which 70 are open and 32 are closed. Of the trials that contain MLLT3 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 27 are phase 1 (14 open), 18 are phase 1/phase 2 (15 open), 41 are phase 2 (31 open), 4 are phase 2/phase 3 (4 open), 7 are phase 3 (3 open), and 4 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in acute myeloid leukemia trials with MLLT3 mutations as inclusion criteria [3].
MLLT4 +
MLLT4 is an inclusion eligibility criterion in 91 clinical trials for acute myeloid leukemia, of which 61 are open and 30 are closed. Of the trials that contain MLLT4 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 26 are phase 1 (13 open), 17 are phase 1/phase 2 (14 open), 35 are phase 2 (27 open), 1 is phase 2/phase 3 (1 open), 7 are phase 3 (3 open), and 4 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in acute myeloid leukemia trials with MLLT4 mutations as inclusion criteria [3].
MNX1 +
MNX1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MNX1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in acute myeloid leukemia trials with MNX1 mutations as inclusion criteria [3].
MYC +
MYC is mutated in 2.2% of acute myeloid leukemia patients [2].
MYC is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain MYC status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
Bet inhibitor gsk525762, allogeneic bone marrow transplantation, and busulfan are the most frequent therapies in acute myeloid leukemia trials with MYC mutations as inclusion criteria [3].
MYH11 +
MYH11 is an inclusion eligibility criterion in 59 clinical trials for acute myeloid leukemia, of which 29 are open and 30 are closed. Of the trials that contain MYH11 status and acute myeloid leukemia as inclusion criteria, 19 are phase 1 (7 open), 8 are phase 1/phase 2 (5 open), 16 are phase 2 (8 open), 3 are phase 2/phase 3 (3 open), 6 are phase 3 (3 open), 1 is phase 4 (1 open), and 6 are no phase specified (2 open) [3].
Cytarabine, fludarabine, and total-body irradiation are the most frequent therapies in acute myeloid leukemia trials with MYH11 mutations as inclusion criteria [3].
NF1 +
NF1 is mutated in 7.33% of acute myeloid leukemia patients [2].
NF1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
Busulfan, fludarabine, and venetoclax are the most frequent therapies in acute myeloid leukemia trials with NF1 mutations as inclusion criteria [3].
NPM1 +
NPM1 is mutated in 16.7% of acute myeloid leukemia patients [2].
NPM1 is an inclusion eligibility criterion in 67 clinical trials for acute myeloid leukemia, of which 58 are open and 9 are closed. Of the trials that contain NPM1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 16 are phase 1 (14 open), 13 are phase 1/phase 2 (12 open), 28 are phase 2 (22 open), 5 are phase 2/phase 3 (5 open), 3 are phase 3 (3 open), and 1 is no phase specified (1 open) [3].
Azacitidine, fludarabine, and cytarabine are the most frequent therapies in acute myeloid leukemia trials with NPM1 mutations as inclusion criteria [3].
NRAS +
NRAS is mutated in 9.81% of acute myeloid leukemia patients [2].
NRAS is an inclusion eligibility criterion in 9 clinical trials for acute myeloid leukemia, of which 5 are open and 4 are closed. Of the trials that contain NRAS status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (1 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (2 open) [3].
Binimetinib, busulfan, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in acute myeloid leukemia trials with NRAS mutations as inclusion criteria [3].
NSD1 +
NSD1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in acute myeloid leukemia trials with NSD1 mutations as inclusion criteria [3].
NUMA1 +
NUMA1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NUMA1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 3 (1 open) [3].
Beta all trans retinoic acid and idarubicin are the most frequent therapies in acute myeloid leukemia trials with NUMA1 mutations as inclusion criteria [3].
NUP214 +
NUP214 is an inclusion eligibility criterion in 86 clinical trials for acute myeloid leukemia, of which 66 are open and 20 are closed. Of the trials that contain NUP214 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 23 are phase 1 (15 open), 15 are phase 1/phase 2 (12 open), 37 are phase 2 (30 open), 2 are phase 2/phase 3 (2 open), 6 are phase 3 (4 open), and 2 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in acute myeloid leukemia trials with NUP214 mutations as inclusion criteria [3].
NUP98 +
NUP98 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in acute myeloid leukemia trials with NUP98 mutations as inclusion criteria [3].
PBX1 +
PBX1 is an inclusion eligibility criterion in 28 clinical trials for acute myeloid leukemia, of which 25 are open and 3 are closed. Of the trials that contain PBX1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 6 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 16 are phase 2 (15 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open) [3].
Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in acute myeloid leukemia trials with PBX1 mutations as inclusion criteria [3].
PDGFRB +
PDGFRB is mutated in 2.2% of acute myeloid leukemia patients [2].
PDGFRB is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Ect-001 expanded cord blood is the most frequent therapy in acute myeloid leukemia trials with PDGFRB mutations as inclusion criteria [3].
PML +
PML is mutated in 3.95% of acute myeloid leukemia patients [2].
PML is an inclusion eligibility criterion in 31 clinical trials for acute myeloid leukemia, of which 18 are open and 13 are closed. Of the trials that contain PML status and acute myeloid leukemia as inclusion criteria, 10 are phase 1 (5 open), 3 are phase 1/phase 2 (1 open), 8 are phase 2 (6 open), 3 are phase 2/phase 3 (3 open), 2 are phase 3 (1 open), and 5 are no phase specified (2 open) [3].
Cytarabine, idarubicin, and fludarabine are the most frequent therapies in acute myeloid leukemia trials with PML mutations as inclusion criteria [3].
PTPN11 +
PTPN11 is mutated in 4.9% of acute myeloid leukemia patients [2].
PTPN11 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PTPN11 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
Busulfan, fludarabine, and venetoclax are the most frequent therapies in acute myeloid leukemia trials with PTPN11 mutations as inclusion criteria [3].
RARA +
RARA is mutated in 0.37% of acute myeloid leukemia patients [2].
RARA is an inclusion eligibility criterion in 31 clinical trials for acute myeloid leukemia, of which 18 are open and 13 are closed. Of the trials that contain RARA status and acute myeloid leukemia as inclusion criteria, 10 are phase 1 (5 open), 3 are phase 1/phase 2 (1 open), 8 are phase 2 (6 open), 3 are phase 2/phase 3 (3 open), 2 are phase 3 (1 open), and 5 are no phase specified (2 open) [3].
Cytarabine, idarubicin, and fludarabine are the most frequent therapies in acute myeloid leukemia trials with RARA mutations as inclusion criteria [3].
RIT1 +
RIT1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains RIT1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
Busulfan, fludarabine, and venetoclax are the most frequent therapies in acute myeloid leukemia trials with RIT1 mutations as inclusion criteria [3].
RPN1 +
RPN1 is an inclusion eligibility criterion in 116 clinical trials for acute myeloid leukemia, of which 92 are open and 24 are closed. Of the trials that contain RPN1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 33 are phase 1 (25 open), 24 are phase 1/phase 2 (19 open), 46 are phase 2 (37 open), 3 are phase 2/phase 3 (3 open), 7 are phase 3 (5 open), and 2 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in acute myeloid leukemia trials with RPN1 mutations as inclusion criteria [3].
RUNX1 +
RUNX1 is mutated in 15.6% of acute myeloid leukemia patients [2].
RUNX1 is an inclusion eligibility criterion in 71 clinical trials for acute myeloid leukemia, of which 40 are open and 31 are closed. Of the trials that contain RUNX1 status and acute myeloid leukemia as inclusion criteria, 21 are phase 1 (9 open), 11 are phase 1/phase 2 (8 open), 22 are phase 2 (13 open), 4 are phase 2/phase 3 (4 open), 6 are phase 3 (3 open), 1 is phase 4 (1 open), and 6 are no phase specified (2 open) [3].
Cytarabine, fludarabine, and cyclophosphamide are the most frequent therapies in acute myeloid leukemia trials with RUNX1 mutations as inclusion criteria [3].
RUNX1T1 +
RUNX1T1 is mutated in 1.2% of acute myeloid leukemia patients [2].
RUNX1T1 is an inclusion eligibility criterion in 62 clinical trials for acute myeloid leukemia, of which 32 are open and 30 are closed. Of the trials that contain RUNX1T1 status and acute myeloid leukemia as inclusion criteria, 19 are phase 1 (7 open), 10 are phase 1/phase 2 (7 open), 17 are phase 2 (9 open), 3 are phase 2/phase 3 (3 open), 6 are phase 3 (3 open), 1 is phase 4 (1 open), and 6 are no phase specified (2 open) [3].
Cytarabine, fludarabine, and total-body irradiation are the most frequent therapies in acute myeloid leukemia trials with RUNX1T1 mutations as inclusion criteria [3].
SF3B1 +
SF3B1 is mutated in 3.46% of acute myeloid leukemia patients [2].
SF3B1 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain SF3B1 status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].
Fludarabine, mln9708, and splicing inhibitor h3b-8800 are the most frequent therapies in acute myeloid leukemia trials with SF3B1 mutations as inclusion criteria [3].
SH2B3 +
SH2B3 is mutated in 1.1% of acute myeloid leukemia patients [2].
SH2B3 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SH2B3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Ect-001 expanded cord blood is the most frequent therapy in acute myeloid leukemia trials with SH2B3 mutations as inclusion criteria [3].
SRSF2 +
SRSF2 is mutated in 10.73% of acute myeloid leukemia patients [2].
SRSF2 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain SRSF2 status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].
Splicing inhibitor h3b-8800, busulfan, and fludarabine are the most frequent therapies in acute myeloid leukemia trials with SRSF2 mutations as inclusion criteria [3].
STAG2 +
STAG2 is mutated in 6.95% of acute myeloid leukemia patients [2].
STAG2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
Busulfan, fludarabine, and venetoclax are the most frequent therapies in acute myeloid leukemia trials with STAG2 mutations as inclusion criteria [3].
TCF3 +
TCF3 is mutated in 0.75% of acute myeloid leukemia patients [2].
TCF3 is an inclusion eligibility criterion in 28 clinical trials for acute myeloid leukemia, of which 25 are open and 3 are closed. Of the trials that contain TCF3 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 6 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 16 are phase 2 (15 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open) [3].
Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in acute myeloid leukemia trials with TCF3 mutations as inclusion criteria [3].
TET2 +
TET2 is mutated in 17.55% of acute myeloid leukemia patients [2].
TET2 is an inclusion eligibility criterion in 4 clinical trials for acute myeloid leukemia, of which 4 are open and 0 are closed. Of the trials that contain TET2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
Cytarabine, azacitidine, and daunorubicin are the most frequent therapies in acute myeloid leukemia trials with TET2 mutations as inclusion criteria [3].
TP53 +
TP53 is mutated in 13.22% of acute myeloid leukemia patients [2].
TP53 is an inclusion eligibility criterion in 87 clinical trials for acute myeloid leukemia, of which 68 are open and 19 are closed. Of the trials that contain TP53 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 22 are phase 1 (13 open), 19 are phase 1/phase 2 (16 open), 37 are phase 2 (31 open), 2 are phase 2/phase 3 (2 open), 4 are phase 3 (3 open), and 2 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in acute myeloid leukemia trials with TP53 mutations as inclusion criteria [3].
TRA +
TRA is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRA status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
Il-15 activated cytokine induced killer cells is the most frequent therapy in acute myeloid leukemia trials with TRA mutations as inclusion criteria [3].
TRB +
TRB is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRB status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
Il-15 activated cytokine induced killer cells is the most frequent therapy in acute myeloid leukemia trials with TRB mutations as inclusion criteria [3].
TRD +
TRD is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRD status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
Il-15 activated cytokine induced killer cells is the most frequent therapy in acute myeloid leukemia trials with TRD mutations as inclusion criteria [3].
TRG +
TRG is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRG status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
Il-15 activated cytokine induced killer cells is the most frequent therapy in acute myeloid leukemia trials with TRG mutations as inclusion criteria [3].
U2AF1 +
U2AF1 is mutated in 4.79% of acute myeloid leukemia patients [2].
U2AF1 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain U2AF1 status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].
Splicing inhibitor h3b-8800, busulfan, and fludarabine are the most frequent therapies in acute myeloid leukemia trials with U2AF1 mutations as inclusion criteria [3].
WHSC1 +
WHSC1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains WHSC1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Mln9708, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in acute myeloid leukemia trials with WHSC1 mutations as inclusion criteria [3].
WT1 +
WT1 is mutated in 4.61% of acute myeloid leukemia patients [2].
WT1 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain WT1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
Anti-cd33 monoclonal antibody bi 836858, idh2 inhibitor ag-221, and pevonedistat are the most frequent therapies in acute myeloid leukemia trials with WT1 mutations as inclusion criteria [3].
ZRSR2 +
ZRSR2 is mutated in 1.86% of acute myeloid leukemia patients [2].
ZRSR2 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain ZRSR2 status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].
Splicing inhibitor h3b-8800, busulfan, and fludarabine are the most frequent therapies in acute myeloid leukemia trials with ZRSR2 mutations as inclusion criteria [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
